Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
Screen a stock
TERMINAL
MD

MDXGStockMimedx Group Inc

Nasdaq Capital Market · Healthcare · US

$3.05 last close 2026-11-20
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment MDXG's does — no target price to set, unlike a price alert.

Stable Ratio screen, 4 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-07-31
Assessed 2026-07-31
4 of 7 pass our own screen — the standards disagree
HTR non-permissible income 1.13%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🔴 AVOID
The main driver: lagging the market by 14.6%. Too many signals pointing the wrong way. Wait for the picture to...
Scores: 1 bullish / 3 bearish
42
of 100
Setup confidence — system conviction, not win probabilityD

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure1 of 5 timeframes bullish · 43.5% aligned
VWAPPrice below VWAP ($3.14)
VolumeRelative volume 4.6× the 20-day average
Momentum10-day rate of change -5.7%
Overall readAVOID

Mimedx Group Inc (MDXG) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-07-31). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Price target
$7.00
+129.5% · 5 analysts
Institutional own.
80.6%
of shares
Momentum (10d)
-5.7%
rate of change
SMC grade
D · 42
43.5% aligned
1.13%
Non-permissible income — HTR, from filings (2025-12-31)
D · 42
SMC grade — 43.5% timeframe alignment
-5.7%
Rate of change (10d)
$7.00
Price target (+129.5%) · 5 analysts
80.6%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to MDXG’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $464.0M as of 2026-11-18. At the 2026-11-20 close it is about $455.3M (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 0.0% (0.0% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 26.5% (26.0% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 30.00% Pass(30.0pp buffer)
Interest-bearing investments 26.03% 30.00% Pass(4.0pp buffer)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)
Usmani Fail 4 of 5 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Interest-bearing investments 45.66% 33.00% Fail(12.7pp over)
Non-liquid assets 40.25% at least 20.00% Pass(20.3pp above the floor)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)
Net liquid assets per share $115.0M under mkt cap $464.0M Pass
MSCI Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 45.66% 33.33% Fail(12.3pp over)
Accounts receivable 59.75% 33.33% Fail(26.4pp over)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)
FTSE Fail 2 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 45.66% 33.33% Fail(12.3pp over)
Accounts receivable 59.75% 50.00% Fail(9.7pp over)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Cash + interest-bearing securities 13.21% 33.00% Pass(19.8pp buffer)
Accounts receivable 4.08% 33.00% Pass(28.9pp buffer)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass(33.0pp buffer)
Cash + interest-bearing securities 12.58% 49.00% Pass(36.4pp buffer)
Accounts receivable 3.88% 49.00% Pass(45.1pp buffer)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass(33.3pp buffer)
Cash + interest-bearing securities 12.58% 33.33% Pass(20.8pp buffer)
Accounts receivable 16.46% 49.00% Pass(32.5pp buffer)
Non-permissible income 1.13% 5.00% Pass(3.9pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 3.9pts
Usmani (% of total assets)non permissible income ratio 3.9pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 3.9pts
MSCI Islamic Index (% of total assets)receivables ratio 26.4pts
Usmani (% of total assets)investments ratio 12.7pts
MSCI Islamic Index (% of total assets)cash and interest ratio 12.3pts

The numbers the ratios are built from

Read from MDXG's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $418.6M 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtShort and long-term borrowings $0 2026-09-30 LongTermDebtNoncurrent, LongTermDebtCurrent
Cash and interest-bearing securitiesCash, equivalents and marketable securities $120.8M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $264.6M 2026-09-30 Assets
Market capDenominator for AAOIFI $464.0M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $928.6M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $896.6M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $4.7M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-10-28, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-25, period ended 2025-12-31. Screened 2026-11-18.

  • Total assets$264.6M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Interest-bearing debt$0
    LongTermDebtNoncurrent $0 · period ended 2026-09-30 · 10-Q filed 2026-10-28
    LongTermDebtCurrent $0 · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Cash and interest-bearing securities$120.8M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Receivables$37.3M
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-10-28
  • Revenue$418.6M
    RevenueFromContractWithCustomerExcludingAssessedTax · period ended 2025-12-31 · 10-K filed 2026-02-25
  • Interest income (non-permissible)$4.7M
    InvestmentIncomeInterest · period ended 2025-12-31 · 10-K filed 2026-02-25
  • Market cap$464.0M
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link

7 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for MDXG. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for MDXG has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Revenue by business segment

How MDXG’s $418.6M of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.

Fiscal year ended 2025-12-31
SegmentShareRevenue
Wound 66.0% $276.3M
Surgical 34.0% $142.3M

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-25 (accession 0001376339-26-000011), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.

What would change the status

The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-18.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (0.0% against a 30% line) would only fail if the market cap fell by 100%, to $0. At the 2026-11-20 close it would read 0.0%.

AAOIFI's investments ratio is $120.8M cash and interest-bearing investments over a market cap of $464.0M (as of 2026-11-18), 26.0% against a 30% line.

At the 2026-11-20 close the market cap is about $455.3M (the stored cap moved by the share price since), so this ratio would read 26.5%; the line is -12% from there. The published status changes only when the company is re-screened.

It would fail if the market cap fell to $402.6M (-13%), about $2.76 a share against $3.18 implied by the screen's own figures.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing).

At the screen's market cap, cash and interest-bearing investments would have to rise by $18.4M to reach the line.

AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold MDXG

4 of the 247 funds whose filed holdings we currently hold own MDXG shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns MDXG.

You may already own it

Widely held U.S. index funds. If you own one, you own MDXG through it. None of them is a Shariah fund; the last column is our look-through of each.

FundMDXG in fundFund compliant by weight
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
Other funds
FundMDXG in fundFund compliant by weight
CFSLX Column Small Cap Fund 0.00% 38%
DFFVX U.S. Targeted Value Portfolio 0.00% 24%

Sorted by MDXG’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names MDXG once, so a bond is not counted as the shares; 1 more fund name MDXG in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding MDXG
InvestorFirmPositionWeightAs of
Peter Brown Renaissance Technologies $11M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $4M 0.0% 2026-09-30
First Eagle First Eagle Investment Management $4M 0.0% 2026-09-30
Israel Englander Millennium Management $1M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $1M 0.0% 2026-09-30
Chuck Royce Royce & Associates $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

7.256.205.154.103.052025-11-242026-05-272026-11-20

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
2.82
S2
2.94
S1
3.03
PIVOT
3.15
R1
3.24
R2
3.36
R3
3.45

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
4.14 – 5.04
±9.9% from 4.59, made 2026-10-02 · resolves 2026-10-09
STRONG SELL
from 19 indicators
78.6% of our last 30385 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
4 buy · 1 neutral · 2 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)22.00BUY
Stochastic %K (14)4.88BUY
CCI (20)-91.36NEUTRAL
Williams %R (14)-95.12BUY
MACD (12,26,9)0.01BUY
ROC (10)-7.86SELL
Momentum (10)-0.26SELL
EMA (10)3.22SELL
SMA (10)3.22SELL
EMA (20)3.43SELL
SMA (20)3.40SELL
EMA (30)3.61SELL
SMA (30)3.72SELL
EMA (50)3.84SELL
SMA (50)4.11SELL
EMA (100)4.08SELL
SMA (100)4.21SELL
EMA (200)4.42SELL
SMA (200)4.12SELL

About Mimedx Group Inc

Healthcare · Biotechnology

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

mimedx.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

🔴 AVOID

The main driver: lagging the market by 14.6%. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.

Scores: 1 bullish / 3 bearish

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H BEARISH 37
🕐 1H BEARISH 98
⏱ 15-Min RANGING 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-5.7%
Rate of change (10d)
4.6×
Volume vs its 20-day average
-0.28
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-17 · Asset managers net 895049 (-19081)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.